| scholarly article | Q13442814 |
| P50 | author | Brian V. Nahed | Q55459537 |
| P2093 | author name string | Tracy T Batchelor | |
| Jay S Loeffler | |||
| Deborah A Forst | |||
| P2860 | cites work | Response criteria for phase II studies of supratentorial malignant glioma | Q44781447 |
| Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance | Q44856308 | ||
| CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas | Q45182713 | ||
| Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy | Q46368296 | ||
| Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype | Q48144051 | ||
| Intraoperative magnetic resonance spectroscopy for identification of residual tumor during low-grade glioma surgery: clinical article | Q48152884 | ||
| Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. | Q48281457 | ||
| MGMT methylation: a marker of response to temozolomide in low-grade gliomas | Q48325983 | ||
| Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade glioma | Q48392946 | ||
| 3-T ultrahigh-field intraoperative MRI for low-grade glioma resection. | Q48414985 | ||
| Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: a SEER analysis | Q48424671 | ||
| Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up | Q48490359 | ||
| Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading? | Q48565954 | ||
| Prognostic factors for survival in adult patients with cerebral low-grade glioma. | Q48629888 | ||
| A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. | Q48896456 | ||
| Molecular markers in low-grade gliomas: predictive or prognostic? | Q55463097 | ||
| Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. | Q55476212 | ||
| Preoperative history and postoperative survival of supratentorial low-grade astrocytomas. | Q55476491 | ||
| Clinical outcome of supratentorial astrocytoma WHO grade II. | Q55477146 | ||
| Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group stud | Q78020353 | ||
| Primary brain tumours in adults | Q83911864 | ||
| IDH1 and IDH2 mutations in gliomas | Q24648948 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Mutations in CIC and FUBP1 contribute to human oligodendroglioma | Q28244895 | ||
| Pilocytic astrocytoma: a disease with evolving molecular heterogeneity | Q28286218 | ||
| Management of low-grade glioma | Q30436353 | ||
| Outcome in adult low-grade glioma: the impact of prognostic factors and treatment | Q30444598 | ||
| Surgery Insight: the role of surgery in the management of low-grade gliomas | Q30444913 | ||
| Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature | Q30960737 | ||
| Diffusion MRI in the early diagnosis of malignant glioma | Q31065350 | ||
| Response criteria for glioma | Q31172444 | ||
| Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial | Q33223508 | ||
| Phase II trial of temozolomide in patients with progressive low-grade glioma | Q33346531 | ||
| Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas | Q33655854 | ||
| Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. | Q33865523 | ||
| BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications | Q33867475 | ||
| Brainstem glioma: a review | Q34628180 | ||
| Adult low-grade glioma: 19-year experience at a single institution. | Q35183129 | ||
| Epidemiology and molecular pathology of glioma | Q36577353 | ||
| IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival | Q36713478 | ||
| Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy | Q37039043 | ||
| Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. | Q37065952 | ||
| Seizure characteristics and control following resection in 332 patients with low-grade gliomas | Q37074101 | ||
| Glioma extent of resection and its impact on patient outcome | Q37170201 | ||
| Quality of life in low-grade glioma patients receiving temozolomide | Q37284235 | ||
| Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis | Q37806773 | ||
| Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors | Q37945513 | ||
| Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas | Q38055666 | ||
| Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers | Q40008535 | ||
| IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. | Q42848152 | ||
| Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy | Q44071779 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 403-413 | |
| P577 | publication date | 2014-03-24 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | Low-grade gliomas | |
| P478 | volume | 19 |
| Q48173326 | Age-associated brain regions in gliomas: a volumetric analysis. |
| Q42366572 | Analysis of long non-coding RNA expression profiles identifies novel lncRNA biomarkers in the tumorigenesis and malignant progression of gliomas |
| Q48268726 | Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma. |
| Q61813300 | Case Report: Clinical Outcome and Image Response of Two Patients With Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol |
| Q64884332 | Chromatin remodeling defects in pediatric brain tumors. |
| Q101356131 | Differentiating non enhancing grade II gliomas from grade III gliomas using diffusion tensor imaging and dynamic susceptibility contrast MRI |
| Q64255604 | Diffuse Low-Grade Glioma - Changing Concepts in Diagnosis and Management: A Review |
| Q97646276 | Downregulation of LUZP2 Is Correlated with Poor Prognosis of Low-Grade Glioma |
| Q89076261 | Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas |
| Q33904348 | Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas. |
| Q42286853 | Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults |
| Q38734366 | Evolving Molecular Genetics of Glioblastoma |
| Q90347000 | Expression patterns and the prognostic value of the EMILIN/Multimerin family members in low-grade glioma |
| Q89602658 | Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma |
| Q58572823 | High expression of GALNT7 promotes invasion and proliferation of glioma cells |
| Q90221019 | Histogram Analysis of Diffusion Weighted Imaging in Low-Grade Gliomas: in vivo Characterization of Tumor Architecture and Corresponding Neuropathology |
| Q60955487 | IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas |
| Q91708327 | Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas |
| Q47581117 | Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma. |
| Q90381161 | Intraoperative Computed Tomography and Awake Craniotomy: A Useful and Safe Combination in Brain Surgery |
| Q38757911 | Life beyond a diagnosis of glioblastoma: a systematic review of the literature |
| Q55456916 | Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics. |
| Q90721346 | PATZ1 Is Overexpressed in Pediatric Glial Tumors and Correlates with Worse Event-Free Survival in High-grade Gliomas |
| Q36985110 | Pathologic aspects of skull base tumors |
| Q48309717 | Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status |
| Q55239801 | Procarbazine, lomustine and vincristine toxicity in low-grade gliomas. |
| Q58117045 | Receptor-Targeted Glial Brain Tumor Therapies |
| Q49637136 | Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis |
| Q92068069 | Screening TCGA database for prognostic genes in lower grade glioma microenvironment |
| Q92501037 | T2 mapping of molecular subtypes of WHO grade II/III gliomas |
| Q36413047 | TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. |
| Q42702324 | Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. |
Search more.